Difference between revisions of "User:Samuelrubinstein"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m |
|||
| Line 1: | Line 1: | ||
[[File:Samuelrubinstein.jpg|thumb|Samuel Rubinstein, MD]] | [[File:Samuelrubinstein.jpg|thumb|Samuel Rubinstein, MD]] | ||
| − | Samuel Rubinstein MD is a hematology-oncology fellow at Vanderbilt University Medical Center. His current research focuses on identifying biomarkers for plasma cell dyscrasias that are useful for prognostication and monitoring response to therapy and exploring ways that evidence-based oncology care can be translated better into clinical practice. His long-term goal is to be a clinical expert in the management of plasma cell dyscrasias and to be performing and designing clinical trials as a principal investigator. He is the HemOnc.org | + | Samuel Rubinstein MD is a hematology-oncology fellow at Vanderbilt University Medical Center. His current research focuses on identifying biomarkers for plasma cell dyscrasias that are useful for prognostication and monitoring response to therapy and exploring ways that evidence-based oncology care can be translated better into clinical practice. His long-term goal is to be a clinical expert in the management of plasma cell dyscrasias and to be performing and designing clinical trials as a principal investigator. He is the HemOnc.org page editor for [[Light-chain (AL) amyloidosis]]. |
Revision as of 18:12, 21 December 2017
Samuel Rubinstein MD is a hematology-oncology fellow at Vanderbilt University Medical Center. His current research focuses on identifying biomarkers for plasma cell dyscrasias that are useful for prognostication and monitoring response to therapy and exploring ways that evidence-based oncology care can be translated better into clinical practice. His long-term goal is to be a clinical expert in the management of plasma cell dyscrasias and to be performing and designing clinical trials as a principal investigator. He is the HemOnc.org page editor for Light-chain (AL) amyloidosis.